STL Volume 20 Number 5

Update on Nivolumab IV infusion (Opdivo®), Pembrolizumab IV infusion (Keytruda®), Sonidegib phosphate capsules (Odomzo®), Azelaic acid 15% foam (Finacea® Foam), Adapalene 0.3% + benzoyl peroxide 2.5% gel (Epiduo® Forte), Deoxycholic acid injection (Belkyra™), Hyaluronic acid gel injectable dermal filler (Restylane® Lyft with Lidocaine), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® (+)

This article reviews the mechanism of action, efficacy, bacterial coverage, and potential side effects for dalbavancin and oritavancin, both semisynthetic lipoglycopeptide antibiotics, and tedizolid, an oxazolidinone.

Apremilast, a selective PDE4 inhibitor, has been shown to reduce the production of pro-inflammatory cytokines. A review of clinical trial data treating psoriasis, considering adverse effects, efficacy and tolerance.